tert-Butyl 3-(methylamino)-9-azabicyclo[3.3.1]nonane-9-carboxylate | 1810070-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-Butyl 3-(methylamino)-9-azabicyclo[3.3.1]nonane-9-carboxylate
• 英文别名: tert-butyl 3-(methylamino)-9-azabicyclo[3.3.1]nonane-9-carboxylate
• CAS: 1810070-17-7
• 化学式: C₁₄H₂₆N₂O₂
• mdl: MFCD29905485
• 分子量: 254.37
• InChiKey: CDNDQGCEQFEPRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.928
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20170312280A1

  公开（公告）日：2017-11-02

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

  该发明提供了式（I）的化合物：其中变量在规范中定义，或其药用盐，这些化合物是JAK激酶的抑制剂。该发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗胃肠道和其他炎症性疾病的方法，以及用于制备这些化合物的过程和中间体。
• HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：EP3889152A1

  公开（公告）日：2021-10-06

  The present invention relates to heteroaromatic derivatives for use as a regulator, a preparation method therefor and a use thereof. In particular, disclosed are compounds represented by general formula (I), preparation methods therefor, pharmaceutical compositions comprising said compounds, and a use thereof as Janus kinase inhibitors in treating inflammatory diseases and tumor-related diseases.

  本发明涉及用作调节剂的杂芳香族衍生物、其制备方法及其用途。特别是，本发明公开了通式（I）代表的化合物、其制备方法、包含所述化合物的药物组合物，以及其作为 Janus 激酶抑制剂在治疗炎症性疾病和肿瘤相关疾病中的用途。
• Pyrimidine compounds as JAK kinase inhibitors
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US10028960B2

  公开（公告）日：2018-07-24

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

  本发明提供了式 (I) 的化合物： 或其药学上可接受的盐，它们是 JAK 激酶的抑制剂。本发明还提供了包含此类化合物的药物组合物、使用此类化合物治疗胃肠道疾病和其他炎症性疾病的方法，以及制备此类化合物的工艺和中间体。
• Methods and compositions for modulating splicing
  申请人：SKYHAWK THERAPEUTICS, INC.

  公开号：US11008572B2

  公开（公告）日：2021-05-18

  Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

  本文描述了可调节基因编码的 mRNA（如 pre-mRNA）剪接的小分子剪接调节剂化合物，以及使用小分子剪接调节剂化合物调节剪接和治疗疾病的方法。
• METHODS AND COMPOSITIONS FOR MODULATING SPLICING
  申请人：SKYHAWK THERAPEUTICS, INC.

  公开号：US20200277289A1

  公开（公告）日：2020-09-03

  Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.